Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dermacyd Femina Pocket BR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dermacyd Femina Pocket BR (Lactic Acid) |
| Name | Type | Description |
|---|---|---|
| Dermacyd Femina Pocket BR (Lactic Acid) | DRUG | Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days |
Inclusion criteria: * Integral skin test in the region; * To use products of the same category; Exclusion criteria: * Lactation or gestation; * Use of anti-inflammatory, anti-histaminic or immunosuppressant drugs; * Cutaneous disease (local or spread) in the evaluation area; * Pathology which may...
Dermacyd Femina Pocket BR is a small molecule product used for hygiene purposes. It is being studied in a Phase 3 clinical trial in Brazil involving healthy female volunteers aged 18 years and older. The product contains lactic acid and is being evaluated for acceptability in this population.
Dermacyd Femina Pocket BR is developed by Sanofi, a company listed on the stock exchange under the ticker SNY. The product is currently in Phase 3 clinical development for hygiene use, with one completed trial in Brazil.
Dermacyd Femina Pocket BR is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the product is being studied for hygiene use in healthy female volunteers.
Dermacyd Femina Pocket BR has one completed clinical trial with the identifier NCT00794612. The trial, titled 'Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability,' was a Phase 3 study conducted in Brazil with 30 female participants aged 18 years and older. The study was uncontrolled and not randomized or double-blind.
Dermacyd Femina Pocket BR contains lactic acid, which is the active component. Lactic acid is known to help maintain the natural acidic pH of the vaginal area, supporting hygiene and comfort. The product is being evaluated for acceptability in a clinical trial setting.